Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030

The Cancer Genome Atlas (TCGA) Utilizing Z0030 NSCLC Patient Samples

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00899535

Enrollment

Registered

2009-05-12

Start date

2008-10-31

Completion date

2013-02-28

Last updated

2016-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

adenocarcinoma of the lung, large cell lung cancer, squamous cell lung cancer, stage I non-small cell lung cancer, stage II non-small cell lung cancer

Brief summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030.

Detailed description

OBJECTIVES: * To investigate the clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens from patients with stage I or II, N0 or N1 (less than hilar) non-small cell lung cancer. OUTLINE: This is a multicenter study. Biological specimens are collected from participating clinical sites and analyzed by transcription profiling of RNA and microRNA; detection of DNA copy number changes and chromosomal rearrangements; epigenetic modifications analyses; and sequencing of genomic segments, genes, and regulatory regions to assess sequence variation. Clinical information associated with each specimen donor is also collected.

Interventions

GENETICDNA analysis

GENETICRNA analysis

GENETICmicroarray analysis

GENETICmutation analysis

GENETICpolymorphism analysis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of non-small cell carcinoma * Primary, untreated disease * Stage I or II (T1 or T2, N0 or non-hilar N1, M0) disease * Any of the following histologies allowed: * Squamous cell carcinoma * Adenocarcinoma (\< 10%) * Large cell carcinoma (high-grade) * Available tumor tissue samples collected on clinical trial ACOSOG-Z0030 and meeting the following criteria: * Snap-frozen and stored at a temperature of -80°C or lower * Specimens may come from any site within the lung or one that is involved by direct regional extension of tumor from the originating site in the lung * No regional lymph node or distant metastases * No recurrent or persistent disease after prior neoadjuvant or adjuvant treatment for lung cancer * Must have matching frozen samples of normal tissue and blood

Design outcomes

Primary

Measure	Time frame
Clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens	Up to 3 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026